secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K/A
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001213900-25-015683
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split
--------------------------------------------------------------------------------

- Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.
- Approved reverse stock split at ratio of 1:2 to 1:15, with exact ratio to be set by the Board.
- David Rosa re-elected as Class II director with 11.7M votes for, 381.7K withheld, 6.0M broker non-votes.
- Ratified Baker Tilly U.S., LLP as independent auditor for FY2025 with 18.1M votes for, 7.4K against.
- Adjournment proposal also approved, with 16.8M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/0001213900-25-015683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/ea0231612-8ka1_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-015683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer